Molecular regulation and pharmacological targeting of the β-catenin destruction complex

Publication date

2017-12-01

Authors

Van Kappel, Eline
Maurice, Madelon MORCID 0000-0001-6885-5361ISNI 0000000359188012

Editors

Advisors

Supervisors

Document Type

Article

Collections

Open Access logo

License

Abstract

The β-catenin destruction complex is a dynamic cytosolic multiprotein assembly that provides a key node in Wnt signalling regulation. The core components of the destruction complex comprise the scaffold proteins axin and adenomatous polyposis coli and the Ser/Thr kinases casein kinase 1 and glycogen synthase kinase 3. In unstimulated cells, the destruction complex efficiently drives degradation of the transcriptional coactivator β-catenin, thereby preventing the activation of the Wnt/β-catenin pathway. Mutational inactivation of the destruction complex is a major pathway in the pathogenesis of cancer. Here, we review recent insights in the regulation of the β-catenin destruction complex, including newly identified interaction interfaces, regulatory elements and post-translationally controlled mechanisms. In addition, we discuss how mutations in core destruction complex components deregulate Wnt signalling via distinct mechanisms and how these findings open up potential therapeutic approaches to restore destruction complex activity in cancer cells. Linked Articles: This article is part of a themed section on WNT Signalling: Mechanisms and Therapeutic Opportunities. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v174.24/issuetoc.

Keywords

Pharmacology

Citation

van Kappel, E C & Maurice, M M 2017, 'Molecular regulation and pharmacological targeting of the β-catenin destruction complex', British Journal of Pharmacology, vol. 174, no. 24, pp. 4575-4588. https://doi.org/10.1111/bph.13922